Salute e Benessere

Preclinical Imaging Market Worth $1,259 million | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841 Browse in-depth TOC on "Preclinical Imaging Market" 83 - Tables40 - Figures165 - Pages Preclinical Imaging Market Scope: Optical Imaging reagents segment is the largest product type of the preclinical reagents market in 2023. Based on reagents, the preclinical imaging...
PR Newswire
27/05/2024

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from May 20, 2024 to May 24, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
27/05/2024

Orthopedic Surgical Robots Market Worth US$ 8.34 Billion by 2034: Fact.MR

The number of surgical procedures conducted each year is increasing across the world, leaving surgeons to have to execute more difficult and time-consuming procedures. Fractures are becoming one of the main forces behind the increased demand for robotic arms; these robotic arms can print a 3D image of the shattered bone fragment, allowing surgeons to connect the 3D portion to the wounded location and treat the patient. The number of surgical procedures conducted each year is increasing across...
PR Newswire
27/05/2024

Global Immunoassay Market to Witness Growth at a CAGR of ~8% by 2030 |…

Key Takeaways from the Immunoassay Market Report Key Takeaways from the Immunoassay Market Report To read more about the latest highlights related to the immunoassay market, get a snapshot of the key highlights entailed in theGlobal Immunoassay Market Report Immunoassay Overview Immunoassay, a cornerstone in medical diagnostics, revolutionizes the detection of various substances within biological samples through the utilization of the immune system's remarkable specificity...
PR Newswire
27/05/2024

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 27 May 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under the…
Nasdaq GlobeNewswire
27/05/2024

Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines…

Key Takeaways from the Acne Vulgaris Market Report Key Takeaways from the Acne Vulgaris Market Report Discover which therapies are expected to grab the major acne vulgaris market share @Acne Vulgaris Market Report Acne Vulgaris Overview Acne vulgaris, commonly known as acne, is a prevalent skin condition that affects millions of people worldwide, typically during adolescence but can persist into adulthood. It occurs when hair follicles become clogged with oil and dead skin...
PR Newswire
27/05/2024

Helsinn and Angelini Pharma sign a partnership agreement renewal to…

Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN ®and MESULID ®in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak RepublicLugano (Switzerland) and Rome (Italy)– May 27, 2024– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Angelini Pharma (“Angelini”), an...
Nasdaq GlobeNewswire
27/05/2024

Hisense Welcomes Goalkeeping Icon Iker Casillas Fernández to UEFA EURO 2024™…

"I am delighted to partner with Hisense and join the 'BEYOND GLORY' campaign which puts the spotlight on celebrating the world's best goalkeepers," explained Iker Casillas. "A goalkeeper's winning reputation is based on their reliability. I am pleased to be invited by Hisense as a Global Ambassador, representing a company relied on by its customers for creating innovative technology that improves their lives." "I am delighted to partner with Hisense and join the 'BEYOND…
PR Newswire
27/05/2024

Changes to the Roche Enlarged Corporate Executive Committee

James Sabry joined Genentech in 2010 as Head of Genentech Partnering. In 2018, he became the Head of Pharma Partnering and a member of the enlarged Corporate Executive Committee, based in Basel, Switzerland. James Sabry completed an MD at Queen's University in Canada and his residency at Harvard Medical School, and then completed a PhD in neuroscience at UCSF. Boris Zaïtra (1972), currently Head of Group Business Development, will be appointed Head of Corporate Business Development...
Nasdaq GlobeNewswire
27/05/2024

Press Release: Sarclisa accepted for FDA priority review for the treatment of…

Sarclisaaccepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myelomaFDA Priority Review granted based on positive results from IMROZ phase 3 study If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of...
Nasdaq GlobeNewswire
27/05/2024

Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for…

"I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care", commented Palani Kumaresan, Head of Roche Diagnostic Solutions. "Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients' needs." "I am delighted that with…
PR Newswire
27/05/2024

Celebrate International Skin Pigmentation Day with Cyspera Boost™

Isobionic Amide: A Beacon of InnovationDeveloped by Dr. B. Kasraee, Isobionic-Amide was identified through careful analysis of the chemical structure of other depigmenting agents, including phenols. Isobionic-Amide has been shown to be the most potent isomer of niacinamide for reduction of the melanin production, resulting in significant depigmentation and enhanced skin brightness. It is recognized as a safe and highly effective molecule for reducing unwanted pigmentation. Isobionic Amide: A...
PR Newswire
25/05/2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria…

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN 2-5 ; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient...
Nasdaq GlobeNewswire
25/05/2024

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3…

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3 Fabhalta showed a favorable safety profile with no new safety signals 1 C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years 4-7 ; currently there are no...
Nasdaq GlobeNewswire
25/05/2024

Appointment of new CFO

ANNOUNCEMENT NO. 269 Appointment of new CFOThe board of ChemoMetec has appointed Kim Nicolajsen as new CFO with effect from 1 July 2024.Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY.The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen...
Nasdaq GlobeNewswire
24/05/2024

Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug…

VANCOUVER, BC, May 24, 2024 /PRNewswire/ -- USA News GroupNews Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 to June 4, industry leaders will unveil new data on late-stage and approved therapies. Recent FDA approvals are also enriching the treatment landscape, offering patients innovative and improved cancer therapies…
PR Newswire
24/05/2024

Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of…

Hugues Lecat appointed Chairman of the Board of Directors of GuerbetVillepinte, 24 May 2024:Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is announcing the appointment of Hugues Lecat as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release of 20 March 2024).Following the approval of his appointment as director at the Annual General Meeting held today at the registered...
Nasdaq GlobeNewswire
24/05/2024

Casino Group: Judgment on FRH and Casino request for further extension under…

Judgment on FRH and Casino request for further extension under Dutch Financial Supervision Act Paris, 24 May 2024Casino Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR0000125585, "Casino") hereby informs as follows: also on behalf of France Retail Holdings S.à r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that FRH and Casino have received a judgment of the Enterprise Chamber of the Amsterdam Court of Appeal, the Netherlands…
Nasdaq GlobeNewswire
24/05/2024

BioSenic provides First Quarter 2024 Business Update

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, May 24, 2024, 17.00am CET –BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces its business update for the first quarter, ended 31 March 2024.Key highlights In January 2024, BioSenic signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds facility, arranged by ABO...
Nasdaq GlobeNewswire
24/05/2024

Positive data from phase 2 NOBLE study of pegcetacoplan presented as…

At one year, of the 11 pegcetacoplan-treated patients with available data: At one year, of the 11 pegcetacoplan-treated patients with available data: Excessive C3c deposits are a marker of disease activity, which can lead to kidney inflammation, damage, and failure. Clearance of both C3c deposits and inflammation allow the kidney to recover and prolong the function of the kidney. Additionally, treatment with pegcetacoplan resulted in sustained improvements in key measures of...
PR Newswire
24/05/2024

Biopreservation Market Worth $7.1 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=842 Browse in-depth TOC on "Biopreservation Market" 361 - Tables53 - Figures315 - Pages Biopreservation Market Scope: The biopreservation media segment is expected to account for the largest share in 2023. The Biopreservation market, by product, has been segmented into...
PR Newswire
24/05/2024

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer…

LOS ANGELES and AMSTERDAM, May24, 2024(GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) and the Amsterdam UMC Cancer Center today announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy. Both Renovaro and Amsterdam UMC emphasize the need to carry out the appropriate corporate and scientific due diligence before taking these next steps. Alongside the...
Nasdaq GlobeNewswire
24/05/2024

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in…

SAN DIEGO and CALGARY, AB, May 24, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. One is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab in newly diagnosed…
PR Newswire
24/05/2024

61st ERA Congress: Semaglutide significantly reduces risk of major kidney…

Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes, compared to those who received placebo. This reduction risk was consistent across both kidney-specific and cardiovascular death outcomes. Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes…
PR Newswire
24/05/2024
Altri  Comunicati